Relationship between clinicopathological parameters and EGFR mutation status in non-small cell lung carcinomas and correlation of PD-L1 expression

被引：0
|
作者：
Cagaptay, S. [1 ]
Gurel, D. [1 ]
Agalar, A. Aysal [1 ]
Ulukus, C. [1 ]
Canaslan, K. [1 ]
Karacam, V. [1 ]
Ulugun, I. [1 ]
Tertemiz, K. C. [1 ]
Oztop, I. [1 ]
机构：
[1] Dokuz Eylul Univ, Izmir, Turkiye
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-20-01
引用
收藏
页码：S437 / S437
页数：1
相关论文
共 50 条
  • [31] PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer
    Xiaohua Shi
    Shafei Wu
    Jian Sun
    Yuanyuan Liu
    Xuan Zeng
    Zhiyong Liang
    Scientific Reports, 7
  • [32] Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion
    Sakai, Hitomi
    Takeda, Masayuki
    Sakai, Kazuko
    Nakamura, Yasushi
    Ito, Akihiko
    Hayashi, Hidetoshi
    Tanaka, Kaoru
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    LUNG CANCER, 2019, 127 : 59 - 65
  • [33] PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer
    Shi, Xiaohua
    Wu, Shafei
    Sun, Jian
    Liu, Yuanyuan
    Zeng, Xuan
    Liang, Zhiyong
    SCIENTIFIC REPORTS, 2017, 7
  • [34] Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer
    Chen, Hefeng
    Ge, Mengxi
    Zhang, Fuchuang
    Xing, Yishi
    Yu, Shicheng
    Chen, Chunzhu
    Zhang, Hougang
    Wang, Xiaoyong
    Gao, Xing
    Chen, Fangtao
    Chen, Peilin
    Zhang, Dadong
    Zhan, Qiong
    Zhu, Youcai
    GENOMICS, 2023, 115 (04)
  • [35] Relationship between PD-L1 Expression and EGFR/HER2 Signaling in Non-Small-Cell Lung Cancer
    Okita, R.
    Maeda, A.
    Shimizu, K.
    Nojima, Y.
    Saisho, S.
    Nakata, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2109 - S2109
  • [36] The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
    Nindra, Udit
    Stevens, Samuel Xavier
    Shahnam, Adel
    Pal, Abhijit
    Adam, Tamiem
    Yip, Po Yee
    Lee, Jenny Hj
    Boyer, Michael J.
    Nagrial, Adnan
    Kao, Steven Chuan-Hao
    Bray, Victoria Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18810 - E18810
  • [37] Correlation analysis between PD-L1 expression, TMB and clinical characteristics in Chinese non-small cell lung cancer
    Yu, Yang
    Fan, Xinglong
    Wei, Yucheng
    Liu, Zimin
    Lian, Zuping
    Han, Hongxia
    Yao, Ming
    Wang, Kai
    CANCER RESEARCH, 2019, 79 (13)
  • [38] PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations
    Mansour, Mohammed S., I
    Malmros, Karina
    Mager, Ulrich
    Lindquist, Kajsa Ericson
    Hejny, Kim
    Holmgren, Benjamin
    Seidal, Tomas
    Dejmek, Annika
    Dobra, Katalin
    Planck, Maria
    Brunnstrom, Hans
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (09)
  • [39] Clinicopathological features of programmed cell death ligand 1 (PD-L1) expression in resected non-small cell lung cancers
    Ohhara, Yoshihito
    Kinoshita, Ichiro
    Tomaru, Utano
    Hatanaka, Kanako C.
    Hatanaka, Yutaka
    Honma, Rio
    Takeuchi, Satoshi
    Shimizu, Yasushi
    Kaga, Kichizo
    Matsuno, Yoshihiro
    Dosaka-Akita, Hirotoshi
    CANCER RESEARCH, 2017, 77
  • [40] Correlation of PD-L1 Expression with Histological Patterns and Treatment Response in Non-Small Cell Lung Cancer
    Beshai, Boulos
    Xu, Bo
    MODERN PATHOLOGY, 2018, 31 : 724 - 724
12345